BIO-RAD LABORATORIES, INC. (BIO)
About BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $2.6B
- Net income
- $759.9M
- Total assets
- $10.6B
- Market cap
- $7.9B
- Gross margin
- 51.9%
- Operating margin
- 1.8%
- Net margin
- 29.4%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.6B
- Cost of revenue
- $1.2B
- Gross profit
- $1.3B
- Operating expenses
- $1.3B
- Operating income
- $47.2M
- Income tax
- $235.6M
- Net income
- $759.9M
- EPS (basic)
- $27.87
- EPS (diluted)
- $27.85
Balance sheet
- Total assets
- $10.6B
- Current assets
- $2.9B
- Total liabilities
- $3.1B
- Current liabilities
- $517.0M
- Shareholders’ equity
- $7.5B
Cash flow
- Operating cash flow
- $532.2M
- Investing cash flow
- -$189.7M
- Financing cash flow
- -$283.2M
- Net cash flow
- $59.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $7.9B
- P/E ratio
- 11.3
- EPS (diluted)
- $27.85
- Shares outstanding
- 25.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 29, 1980
Bio-rad Laboratories, Inc. (BIO) Stock Price
- Profitable — net income of $759.9M in FY2025.
- Revenue grew 1% from FY2020 to FY2025.
- Gross margin of 51.9%, net margin 29.4%.
- Trading 7% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 11.3.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BIO-RAD LABORATORIES, INC..
Write a review
News about BIO-RAD LABORATORIES, INC.
News & sentiment via Polygon.io
Bio-rad Laboratories, Inc.: frequently asked questions
Is Bio-rad Laboratories, Inc. an American company?
Yes — Bio-rad Laboratories, Inc. is an American company headquartered in Hercules, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Bio-rad Laboratories, Inc. headquartered?
Bio-rad Laboratories, Inc. is headquartered in Hercules, California, United States.
Is Bio-rad Laboratories, Inc. publicly traded?
Yes — Bio-rad Laboratories, Inc. is a publicly traded company. Its stock trades under the ticker symbol BIO on the NYSE.
What does Bio-rad Laboratories, Inc. do?
Bio-rad Laboratories, Inc. is an American Medical Devices company in the Health & Beauty sector.
